Jackie S. Fairweather, RN

home / authors / jackie-s-fairweather-rn

Articles

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Ritsuko Komaki, MD;Nora A. Janjan, MD;Jaffer A. Ajani, MD;Patrick M. Lynch, MD;Jackie S. Fairweather, RN;Isaac Raijman, MD;George R. Blumenshein, MD;Linus Ho, MD, PhD;Peter W. T. Pisters, MD;Barry W. Feig, MD;Garrett L. Walsh, MD;Richard Pazdur, MD

December 3rd 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly

Irinotecan and Cisplatin in Advanced Gastric or Gastroesophageal Junction Carcinoma

Jaffer A. Ajani, MD;Jackie S. Fairweather, RN;Peter W. T. Pisters, MD;Chulsip Charnsangavej, MD

December 1st 2000

Chemotherapy for advanced gastric and gastroesophageal junction carcinomas remains suboptimal. Both irinotecan (Camptosar) and cisplatin (Platinol) are active against this group of malignancies. This article focuses